Orexo AB to Present Q3 2025 Interim Report and Project Updates
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Orexo AB...
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
UPPSALA, Sweden , Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a powder-based intranasal semaglutide...